HUMEDIX Co.LTD.

As of March 31, 2026, HUMEDIX Co.LTD. carries a market capitalization of 372.49B, placing it among publicly traded companies globally. Its enterprise value stands at 248.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HUMEDIX Co.LTD.'s next confirmed earnings release is scheduled for November 16, 2026.

As of March 31, 2026, HUMEDIX Co.LTD. has 11.10M shares outstanding.

As of March 31, 2026, HUMEDIX Co.LTD. trades at a trailing price-to-earnings ratio of 6.86. The price-to-sales ratio is 2.07, and the price-to-book ratio stands at 1.20.

As of March 31, 2026, HUMEDIX Co.LTD. trades at an EV/EBITDA multiple of 4.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. HUMEDIX Co.LTD. trades at an EV/FCF ratio of 7.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 248.18B versus a market cap of 372.49B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, HUMEDIX Co.LTD. maintains a current ratio of 8.03, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, HUMEDIX Co.LTD. posted a return on equity (ROE) of 18.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.10 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 16.99, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.57, useful for judging operating efficiency across full business cycles. The company generates approximately 455.71M in revenue per employee across its workforce of 374.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.63 indicates how many times HUMEDIX Co.LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, HUMEDIX Co.LTD. recorded 13.91B in income tax expense. That works out to an effective tax rate of 21.31, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 65.26B, leaving 51.35B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, HUMEDIX Co.LTD.'s stock has declined approximately 52.69% over the past 52 weeks. The 50-day moving average sits at 25,499.00, while the 200-day moving average is 31,605.50.

Over the twelve months ended March 31, 2026, HUMEDIX Co.LTD. generated 170.43B in revenue and converted that into 51.35B in net income, yielding earnings per share of 4,884.34. EBITDA reached 50.10B, while operating income came in at 39.81B.

As of March 31, 2026, HUMEDIX Co.LTD. holds 125.29B in cash and equivalents against 978.06M in total debt, resulting in a net debt position of -50.10B. Total book value stands at 310.60B, with working capital of 159.98B providing operational flexibility.

HUMEDIX Co.LTD. produced 42.84B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -7.88B in capital expenditures, free cash flow totaled 34.96B - equivalent to 3,328.15 per share.

Over the twelve months ended March 31, 2026, HUMEDIX Co.LTD. posted a gross margin of 45.42, reflecting its pricing power and cost economics. The operating margin of 23.36 and net profit margin of 30.13 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, HUMEDIX Co.LTD. paid dividends of 706.38 per share. The dividend payout ratio of 14.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.91, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.08, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HUMEDIX Co.LTD. shareholders.

HUMEDIX Co.LTD.'s most recent stock split took place on December 27, 2018 with a 100:107 split ratio.

As of March 31, 2026, HUMEDIX Co.LTD. has an Altman Z-Score of 10.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.